Live Bacteria for Inflammatory Bowel Disease Treatment
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease do not provide a cure and often have limited effectiveness in reducing inflammation and symptoms.
Innovation Solution
A method using a composition containing live beneficial bacteria like Bacillus coagulans or Clostridium butyricum, administered orally or as a dietary supplement, to inhibit intestinal inflammation and alleviate symptoms by forming a protective layer, secreting acidic substances, and promoting digestion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (drugs, nutrition supplements, surgery) are used for IBD, then disease symptoms can be controlled and remission can be induced, but the disease cannot be cured and treatment effectiveness is limited
Solution Approach 1:
The live beneficial bacteria (Bacillus coagulans and Clostridium butyricum) establish themselves in the patient's intestine and perform self-service by continuously producing protective substances, maintaining the protective layer, and regulating the immune system autonomously without requiring continuous external medication intervention
Solution Approach 2:
The live beneficial bacteria act as intermediaries between the harmful pathogens and the host immune system, producing protective layers and acidic substances that mediate the interaction, reducing direct harmful effects on intestinal tissues while modulating immune responses
2Object-generated harmful factors
If live beneficial bacteria are administered to treat IBD, then inflammation can be effectively reduced and symptoms alleviated, but the mechanism involves complex biological processes (forming protective layers, secreting acidic substances, promoting digestion)
Solution Approach 1:
The complex biological mechanism is segmented into three distinct functional components: (1) formation of protective layers on intestinal mucosa, (2) secretion of acidic substances to inhibit pathogens, and (3) promotion of digestion through enzyme production, allowing each function to be independently optimized and understood
3Reliability
If high doses of live bacteria (10^6 to 10^12 cfu per day) are administered, then better therapeutic effect is achieved, but formulation stability and delivery to the intestine become more challenging
Solution Approach 1:
The patent utilizes parameter changes in the bacterial composition, specifically selecting bacteria that can withstand varying environmental conditions (pH, temperature, oxygen levels) throughout the gastrointestinal tract, and formulating with protective carriers that maintain bacterial viability through the harsh stomach environment to the intestine
Solution Approach 2:
The invention employs composite formulation systems combining live beneficial bacteria with protective carriers, prebiotics, and stabilizing agents that work synergistically to maintain bacterial composition stability during storage and delivery while ensuring sufficient viable count reaches the intestine
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The live beneficial bacteria effectively reduce inflammation, alleviate symptoms like abdominal pain and diarrhea, and lower inflammatory factors, demonstrating better efficacy than conventional treatments in animal models and human trials.
Implementation Method 1
forming a protective layer
Implementation Method 2
secreting acidic substances
Implementation Method 3
promoting digestion
Data Source
AI summary
This invention relates to using live beneficial bacteria for treating inflammatory bowel disease, such as ulcerative colitis and Crohn's disease.
